Navigation Links
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
Date:4/25/2008

PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay the Biologics License Application (BLA) submission for ipilimumab, an investigational immunotherapy for patients with advanced metastatic melanoma. The FDA has requested additional overall survival (OS) data to further demonstrate the benefit of ipilimumab. Revised timelines are under development, but a BLA for ipilimumab will not be submitted to the FDA in 2008.

The randomized Phase 3 trial evaluating the efficacy of ipilimumab in combination with dacarbazine versus dacarbazine alone in patients with untreated unresectable Stage III or Stage IV melanoma is ongoing under Special Protocol Assessment (SPA). The companies are engaged in discussions with the FDA to change the primary endpoint in this trial from progression free survival (PFS) to OS. A potential submission for melanoma would include survival data from patients in the Phase 2 second-line studies and the randomized Phase 3 first-line trial currently ongoing.

Bristol-Myers Squibb and Medarex remain committed to the development of ipilimumab. The companies also have ongoing Phase 2 studies in hormone-refractory prostate cancer and lung cancer as well as a Phase 3 study, to be initiated shortly, in adjuvant melanoma.

Twelve abstracts evaluating ipilimumab in melanoma will be presented at the American Society
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
2. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
4. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
5. Medarex to Present at the JPMorgan Small/Mid Cap Conference
6. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
7. Former Bristol-Myers Squibb Senior Vice President Indicted for Lying to the Federal Government About Popular Blood-Thinning Drug
8. Bristol-Myers Squibb to Announce Results for the First Quarter of 2008 on April 24
9. Bristol-Myers Squibb to Present at Healthcare Conferences
10. Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
11. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
(Date:5/22/2015)... ZH Healthcare (ZH), ... today that Bill Lane, joins ZH’s Advisory Board. ... BlueEHS,a first of its kind, Freemium SaaS, Electronic ... Health Records (EHR) with an integrated practice management ... patient portal, and more. Combined with its Revenue ...
(Date:5/22/2015)... Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they are ... cosmetic, restorative and other dental treatments. At consultations, ... interest them. Questions regarding what certain treatments can ... also be covered during this initial appointment. If ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Medivo, Inc., ... “Positivity Rates and Genotype Results in ‘Baby Boomers’ Screened ... from a Nationwide Lab Test Database” at Digestive Disease Week, ... Medivo’s Clinical Affairs and Analytics team members Carol Smyth, MB; ... and Andrea Parker, MSI, along with Nancy Reau, MD from ...
(Date:5/22/2015)... 22, 2015 A Phase 3 ... American Society of Clinical Oncology (ASCO)’s annual meeting ... rates for those patients who received bevacizumab in ... pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is an antibody ... is already routinely used to treat many other ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... 7 Vion,Pharmaceuticals, Inc. (Nasdaq Capital Market: VION) ... that the Company had regained,compliance with Marketplace Rule ... Stock had traded at $1.00 per share or ... Vion Pharmaceuticals, Inc. is committed to extending the ...
... MGT Capital Investments,Inc. (Amex: MGT ), ... ("HCIT") sector, today commented on the American Cancer,Society,s ... its colon cancer screening guidelines. MGT Capital Investment,s,Medicsight ... exchange under,"MDST," is an industry leader in the ...
... March 7 Novavax, Inc.,(Nasdaq: NVAX ) a ... and Chief Executive Officer, will be presenting at,the Partnering ... on March 11,2008 in Washington D.C. Dr. Singhvi will ... the area of vaccine development to,protect against H5N1 pandemic ...
... Calif., March 7 Genoptix, Inc.,(Nasdaq: GXDX ), ... in the 11th Annual Lehman Brothers Global,Health Care Conference ... Fla.,March 18 - 20, 2008., Dr. Tina Nova ... will present at the conference on Tuesday, March 18, ...
... to protect its Intellectual Property that, has been employed in Minimally Invasive ... ... decade, MARIETTA, Ga., March 7 In a much anticipated decision,Judge ... personally liable for expenses and attorneys,fees incurred by ERBE while defending against ...
... Liverpool School of Tropical Medicine has received a $30 million ... the control and treatment of malaria in pregnancy in Africa, ... directly benefit the 50 million women who face exposure to ... research at Liverpool and at 38 partner institutions in 27 ...
Cached Medicine News:Health News:Vion Pharmaceuticals Regains NASDAQ Listing Compliance 2Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 2Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 3Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 4Health News:Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference 2Health News:ERBE Perseveres Yet Again in Opposition to Dr. Jerome Canady, and is Awarded More Than One Million Dollars 2Health News:LSTM to lead $30 million research program into malaria in pregnancy 2
(Date:5/21/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6csvbs/market_assessment ... "Market Assessment of Respiratory Diagnostics in the United ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service provides ... in the United States ... provides detailed analysis of the current and forecasted ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: ... employee Greg Watson , the company,s vice president of ... the company,s common stock, at a per share exercise price ... The stock option was granted pursuant to Cardica, Inc.,s Inducement ... in May 2015 under Rule 5653(c)(4) of the Nasdaq Global ...
(Date:5/21/2015)... 21. Mai 2015 Dipexium ... ein Unternehmen für Arzneimittel im fortgeschrittenen ... und Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) ... eine wissenschaftliche Posterpräsentation an, welche das ... vorstellt, OneStep-1 und OneStep-2, in der ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Cardica Announces New Employment Inducement Grant 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... gloves were designed with the surgeon in ... protection, and value. It offers comfort and ... dry hands. The broader, anatomical design allows ... surface offers sensitivity and an effective grip, ...
The Next Generation in Operating Room Equipment and Management Solutions is here Today. NuBoom is a self-contained, pedestal-mounted boom that houses medical, audio and visual equipment....
... versatility and positioning, look to BERCHTOLD's OPERON ... design and 770 lb. weight capacity ensures ... specialties and patient sizes. The radiolucent phenolic ... with a C-arm. An intuitive remote control ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z37,158-0) ... assistance. Color: colour-coded ...
Medicine Products: